Finland · Delayed Price · Currency is EUR Aiforia Technologies Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined 46% year-over-year due to delayed customer ramp-up and a shift to recurring revenue models, while the order book and clinical customer base remained stable. Strategic partnerships, product expansion, and new financing position the company for growth in a rapidly expanding AI diagnostics market.
Fiscal Year 2025
-
Revenue grew 24% year-over-year, with clinical sector up 68% and accelerating in H2. Investments in AI and regulatory compliance drove portfolio expansion, while recurring revenue and major wins in Europe and the U.S. support scale-up ambitions.
-
Order book grew 58% year-over-year, with clinical revenue up 60% and major European customer wins. Revenue was flat overall due to timing of deliveries, but strong pipeline and regulatory progress position the company for accelerated growth in H2 and beyond.
Fiscal Year 2024
-
Clinical market now drives half of revenue, with 19% overall growth and a 118% order book increase. Major hospital deals and new regulatory-approved AI models fuel expansion, while cost control and a strong cash position support the goal of break-even by year-end.
-
Revenue grew 43% year-over-year, driven by major clinical wins in Europe and a growing order book. Profitability is targeted for 2027, with strong cash reserves and a focus on scaling delivery and expanding key accounts.